Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00132821 · ClinicalTrials.gov registry record · Phase 4
Impact of Smoking Cessation on Sleep - 5
A Phase 4 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 4
- Development phase
- 59
- Enrollment target
NCT00132821: Completed Phase 4 study, sponsored by National Institute on Drug Abuse (NIDA).
NCT00132821 is a Phase 4 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 59 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00132821, a Phase 4 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 59 participants
- Enrollment target
Study Summary
Smoking is a major health problem with a direct link to elevated heart- and lung-related problems. Nicotine is highly addictive, which makes quitting difficult and relapse after quitting highly probable. Any type of sleep disturbance may make quitting even harder. The purpose of this study is to evaluate the effect of bupropion and nicotine replacement therapies (NRT) on sleep disturbances. In turn, this might show how such medications affect attempts at smoking cessation.
Interventions
- DRUG Transdermal Nicotine Patch
- DRUG Bupropion
- DRUG Placebo Bupropion
- DRUG Placebo transdermal nicotine patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2005-08 |
| Est. Completion | 2009-05 |
| Phase | Phase 4 |
What the finished NCT00132821 record still lists
NCT00132821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 4 interventions - of which Transdermal Nicotine Patch is the first listed.
NCT00132821 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00132821 about?
NCT00132821 is a clinical study titled "Impact of Smoking Cessation on Sleep - 5". Smoking is a major health problem with a direct link to elevated heart- and lung-related problems. Nicotine is highly addictive, which makes quitting difficult and relapse after quitting highly probable. Any type of sleep disturbance may make quitting even harder. The purpose of this study is to eva...
What is the current status of trial NCT00132821?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 59 participants. The study started on 2005-08. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00132821?
The interventions under investigation include: Transdermal Nicotine Patch (DRUG), Bupropion (DRUG), Placebo Bupropion (DRUG), Placebo transdermal nicotine patch (DRUG).
Who is sponsoring clinical trial NCT00132821?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00132821's enrollment target sits among peer trials
59 1202nd of 2000 higher than 796 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia